Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutic Com
(NQ:
SAGE
)
12.29
+0.12 (+0.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sage Therapeutic Com
< Previous
1
2
3
4
Next >
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
July 17, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
June 11, 2024
From
Sage Therapeutics
Via
Business Wire
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Participate in Upcoming May Investor Conferences
May 07, 2024
From
Sage Therapeutics
Via
Business Wire
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
April 25, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
April 17, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
April 11, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at Upcoming March Investor Conferences
February 28, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
February 14, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
January 31, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Changes to Board of Directors
January 08, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
January 02, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Biogen Inc.
Via
GlobeNewswire
Sage Therapeutics to Present at Upcoming November Investor Conferences
November 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
November 07, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 24, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
October 18, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at Upcoming September Investor Conferences
September 06, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm
September 01, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
September 01, 2023
Via
ACCESSWIRE
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
August 31, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Blink, Lovesac, and Sage and Encourages Investors to Contact the Firm
August 27, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the Firm
August 21, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
August 14, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
August 07, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
August 04, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 04, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.